Pharm
Protease Inhibitor
search
Protease Inhibitor
See Also
Anti-Retroviral Therapy
Mechanism
Prevent HIV from being assembled
Prevent release from infected
CD4+ Cell
s
Protocols
Most Protease Inhibitors are "boosted" with concurrent use of
Ritonavir
(
Norvir
)
Limited by adverse gastrointestinal effects
Preparations- suffix '/r' added when combined with Ritonavir
Amprenavir (Agenerase)
Atazanavir (
Reyataz
, ATV or ATV/r)
Unboosted (without
Ritonavir
) has least adverse effect on lipids
Darunavir
(DRV or DRV/r)
Less adverse effects on lipid profile
Fosamprenavir
(
Lexiva
, FPV or
FPV/r
)
Indinavir
(
Crixivan
)
Lopinavir
with
Ritonavir
(
Kaletra
,
LPV/r
)
Nelfinavir
(
Viracept
)
Ritonavir
(
Norvir
, /r)
Saquinavir
(Fortovase)
Saquinavir
mesylate (
Invirase
)
Tipranavir
(
Aptivus
)
Precautions
Saquinavir
and
Saquinavir
mesylate are not equivalent
Adverse Effects
See each individual agent for specific adverse effects
Nephrolithiasis
(
Indinavir
)
Severe
Diarrhea
(
Nelfinavir
)
Gastrointestinal upset
Lipodystrophy
Insulin Resistance
Manage with lifestyle changes (diet,
Exercise
)
Consider medications
Thiazolidinedione
s (eg
Rosiglitazone
,
Pioglitazone
)
Glucophage
Severe lipid abnormalities
Effects
Hypertriglyceridemia
Low HDL
Management
Consider Atazanavir (unboosted or boosted) or boosted
Darunavir
(DRV)
Can be treated with
Pravastatin
(see below)
Resolves with discontinuation of Protease Inhibitor
Hepatotoxicity
Associated with concurrent use of other HIV agents
Associated with comorbid
Hepatitis C
Osteopenia
Drug Interactions
Drug Interaction
s are common
Protease Inhibitors cause the most
Drug Interaction
s of all
Antiretroviral
s
Statin
drugs (used for PI-induced lipid abnormalities)
Pravastatin
is first choice
Statin
for use with PI
Rosuvastatin
(
Crestor
) or
Atorvastatin
(
Lipitor
) may also be used with caution
Do not use
Simvastatin
or
Lovastatin
with PI
Apixiban or
Rivaroxaban
Metabolized by
CYP3A4
and
P-Glycoprotein
Protease Inhibitors strongly inhibit
CYP3A4
or
P-Glycoprotein
, with associated bleeding risk
Monitoring
Fastin
g lipid panel with
Glucose
every 3-6 months
References
(1998) Med Lett Drugs Ther 40(1041):115 [PubMed]
(2009) Treat Guidel Med Lett 7(78): 11-22 [PubMed]
Reust (2011) Am Fam Physician 83(12): 1443-51 [PubMed]
Type your search phrase here